Precision Medicine

Born from a Novartis mega-deal, Atrium Therapeutics aims its novel RNA platform at rare, untreatable genetic heart diseases. Will its strategy succeed?

With U.S. cancer centers tripling adoption of its targeted drug delivery device, RenovoRx signals a potential shift in treating solid tumors.

A key European panel recommends Dupixent for children with chronic hives, offering a potential first-of-its-kind targeted therapy for a difficult condition.

The biopharma firm beats 2025 guidance on strong specialty and generic sales, forecasting another year of growth fueled by new product launches.

A high-stakes legal battle unfolds as Xeris sues to block generic versions of its blockbuster Cushing's syndrome drug, Recorlev, until 2040.

Tectonic Therapeutic reports key clinical progress in two distinct rare diseases, backed by a strong cash position and new leadership for its next phase.

One in 10 Canadians has kidney disease, often with no symptoms. Experts urge immediate action as this silent crisis strains lives and our healthcare system.

With Phase 3 epilepsy results for its lead drug azetukalner due in March, Xenon reveals a major R&D spend and a cash runway to fuel its broad pipeline.

New research reveals a massive trust gap in healthcare AI as overall confidence drops. Why are users believers while the vast majority of Americans remain wary?

A new skincare brand is skipping mass marketing, embedding its products with veterans, skiers, and melanoma researchers to redefine sun protection.

After a strong 2025, Viatris unveils a plan for $650M in savings, a 10% workforce cut, and a focus on six new drugs to fuel future innovation.

With soaring sales for its rare obesity drug IMCIVREE, Rhythm Pharmaceuticals faces a critical March FDA decision that could unlock a massive new market.

New analyses of Upstream Bio's verekitug aim to prove its true effectiveness for nasal polyps, setting the stage for a competitive showdown.

A novel mouse model with human immune receptors promises to slash the high failure rate of antibody therapies, accelerating life-saving treatments.

With its strategic pivot to high-growth Med Tech paying off, all eyes are on AngioDynamics' CEO presentation at the upcoming Leerink healthcare conference.

PROCEPT BioRobotics reports record Aquablation procedures but lowers 2026 revenue guidance, signaling a strategic shift for long-term profitability.

The biopharma company shatters records with 51% growth in its key drug, ASCENIV, and outlines a strategic overhaul aimed at long-term market dominance.

With cash to last until 2027 but mounting losses, Alector stakes its future on its ABC platform and a pivotal Alzheimer's trial milestone.

Eton Pharmaceuticals wins landmark FDA approval for DESMODA, a breakthrough liquid drug set to transform care for a rare condition by enabling precise, safe dosing.

Amid a surge in MedTech M&A, Piper Sandler appoints 25-year veteran Aamer Naseer to steer its life sciences outsourcing and B2B technology groups.